MRFAP1L1 Activators
MRFAP1L1 (Morf4 family associated protein 1-like 1) activators are a category of chemical agents designed to selectively modulate the activity of the protein MRFAP1L1. MRFAP1L1 is a member of the MORF4/MRG (Mortality factor on chromosome 4/MORF4 related gene) family which plays a role in the regulation of chromatin structure and gene expression. The protein itself is relatively less characterized compared to other members of the MORF4/MRG family, but it is understood to have a role in the nuanced modulation of chromatin dynamics. MRFAP1L1 activators interact with the protein at specific binding sites, inducing a conformational change that can upregulate its activity. The precise mechanism by which these molecules activate MRFAP1L1 can vary, with some directly binding to the active site, while others may bind to allosteric sites, which are distinct from the active site and can modulate protein function indirectly.
Chemically, MRFAP1L1 activators are diverse, encompassing a range of small molecules, peptides, or other macromolecules that have been identified through various techniques such as high-throughput screening, or bioprospecting. The structure-activity relationship (SAR) of these activators is a subject of ongoing research, aiming to elucidate the precise molecular interactions that govern their activity. This entails understanding the physicochemical properties of the activators, such as hydrophobicity, charge, molecular weight, and hydrogen bonding potential, which are critical in determining their affinity and specificity for MRFAP1L1. The development of these activators requires a deep understanding of the three-dimensional structure of MRFAP1L1, particularly the identification of key amino acids within the activation site that are responsible for the molecular recognition and binding of these chemical agents. Through such insights, the field aims to advance the understanding of the regulatory mechanisms of MRFAP1L1 without delving into the direct applications of such knowledge in medical contexts.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, which increases intracellular cAMP levels. Elevated cAMP activates PKA, which could phosphorylate substrates that indirectly enhance the activity of MRFAP1L1 by modulating its interaction with binding partners such as MORF4L1. | ||||||
Ibuprofen | 15687-27-1 | sc-200534 sc-200534A | 1 g 5 g | $52.00 $86.00 | 6 | |
Ibuprofen is known to inhibit cyclooxygenase (COX). This inhibition can reduce prostaglandin synthesis, which might decrease inflammatory signaling pathways that could otherwise sequester MRFAP1L1, thus indirectly increasing its availability and function. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram inhibits PDE4, leading to increased cAMP levels similar to Forskolin. The subsequent activation of PKA could lead to phosphorylation events that enhance MRFAP1L1 interaction with protein partners involved in chromatin remodeling. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. By preventing deacetylation, it can maintain a more open chromatin state that may facilitate the access of MRFAP1L1 to regions where it exerts its functions. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is an activator of protein kinase C (PKC). PKC activation can result in downstream effects that enhance the protein-protein interactions necessary for MRFAP1L1 function. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine inhibits DNA methyltransferases, which could lead to a reduction in DNA methylation. Demethylated DNA might allow for increased MRFAP1L1 interaction with chromatin, enhancing its functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K, it can modulate AKT signaling, potentially altering the phosphorylation state of MRFAP1L1 or its binding partners, thus enhancing MRFAP1L1's role in the nucleus. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which can lead to altered translation regulation. This may indirectly enhance MRFAP1L1's interactions with other nuclear proteins due to changes in their expression levels. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin can inhibit NF-κB signaling, which may indirectly enhance the availability or interaction of MRFAP1L1 with its nuclear binding partners by reducing competitive signaling pathways. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol activates SIRT1, a deacetylase, which in turn can deacetylate and activate various transcription factors and proteins. This activation could indirectly enhance the function of MRFAP1L1 through improved chromatin interactions. | ||||||